KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Receivables - Net (2016 - 2022)

Historic Receivables - Net for TherapeuticsMD (TXMD) over the last 13 years, with Q3 2022 value amounting to $32.2 million.

  • TherapeuticsMD's Receivables - Net fell 1402.33% to $32.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $32.2 million, marking a year-over-year decrease of 1402.33%. This contributed to the annual value of $36.2 million for FY2021, which is 1171.74% up from last year.
  • Latest data reveals that TherapeuticsMD reported Receivables - Net of $32.2 million as of Q3 2022, which was down 1402.33% from $45.8 million recorded in Q2 2022.
  • In the past 5 years, TherapeuticsMD's Receivables - Net ranged from a high of $45.8 million in Q2 2022 and a low of $5.1 million during Q1 2018
  • Its 5-year average for Receivables - Net is $24.1 million, with a median of $24.1 million in 2020.
  • In the last 5 years, TherapeuticsMD's Receivables - Net skyrocketed by 22675.18% in 2019 and then crashed by 1402.33% in 2022.
  • Quarter analysis of 5 years shows TherapeuticsMD's Receivables - Net stood at $11.1 million in 2018, then soared by 120.5% to $24.4 million in 2019, then skyrocketed by 32.74% to $32.4 million in 2020, then rose by 11.72% to $36.2 million in 2021, then dropped by 11.11% to $32.2 million in 2022.
  • Its Receivables - Net stands at $32.2 million for Q3 2022, versus $45.8 million for Q2 2022 and $35.4 million for Q1 2022.